allogeneic umbilical cord derived mesenchymal stem cell therapy （Meribank Biotech Co Ltd）

N/A

Report date: 2024/07/16 20:00:09

Base Information

Drug Nameallogeneic umbilical cord derived mesenchymal stem cell therapy （Meribank Biotech Co Ltd）
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derived
Mechanisms of ActionStem cell replacements
TargetsUpdating
Therapy Area/IndicationsPathologic ProcessesCystic Adenomatoid Malformation of Lung, Congenital
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMeribank Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMeribank Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsPathologic ProcessesCystic Adenomatoid Malformation of Lung, Congenital
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A